Gynesonics, a medical device company specializing in women’s healthcare, recently announced the creation of a new Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure, used in the treatment of uterine fibroids. The American Medical Association (AMA), in collaboration with the American College of Obstetrics and Gynecology (ACOG), has assigned code 58580 to this procedure, reflecting its integration into current medical practices and proven clinical efficacy.
Effective from January 1, 2024, the code—CPT 58580—specifically describes transcervical ablation of uterine fibroid(s) with ultrasound guidance using radiofrequency, including intraoperative ultrasound guidance and monitoring. This classification is a significant step in standardizing and recognizing the procedure in medical services across the United States.
The Sonata Procedure, at the heart of this development, offers a non-invasive alternative to traditional surgical options for the treatment of uterine fibroids, such as hysterectomy and myomectomy. Using integrated ultrasound for guidance, the Sonata System enables the precise treatment of various fibroid types, sizes, and locations through a transcervical approach, negating the need for incisions or tissue removal and preserving the uterus.
Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said: “We are very pleased that the AMA has established a new Category I code that applies to our Sonata Procedure for the treatment of uterine fibroids. This unique code will simplify the process for providers and insurers of submitting and processing claims on behalf of their patients. The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States. We sincerely appreciate the efforts of the AMA and the CPT Editorial Panel to establish a Category 1 code, acknowledging the innovation and efficacy of the Sonata transcervical fibroid ablation.”
Uterine fibroids, benign masses located in or around the uterus, affect a significant portion of women in their childbearing years. They can lead to a range of symptoms including abnormal uterine bleeding, pelvic pain, and increased urinary frequency, among others. The Sonata System’s innovative approach to treating these fibroids represents a significant advancement in women’s healthcare.
